Meeting
2022 ASCO Annual Meeting
Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy.
Authors
Andrea Pretta
Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy
Andrea Pretta , Dario Spanu , Riccardo Giampieri , Eleonora Lai , Erika Cimbro , Federica Pecci , Francesca Balconi , Alessio Lupi , Marta Pozzari , Sara Murgia , Fabio Bardanzellu , Antonio Maccioni , Fabiana Contu , Mara Persano , Clelia Donisi , Pusceddu Valeria , Marco Puzzoni , Pina Ziranu , Rossana Berardi , Mario Scartozzi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4153)
DOI
10.1200/JCO.2022.40.16_suppl.4153
Abstract #
4153
Poster Bd #
138
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
First line gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma.
First Author: Pat Gulhati
Poster
2017 Gastrointestinal Cancers Symposium
Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).
First Author: Hui-Li Wong
Poster
2017 Gastrointestinal Cancers Symposium
Prognostic factors in patients (pts) with advanced biliary tract cancer (BTC) treated with first-line gemcitabine plus cisplatin (GEMCIS): Retrospective analysis of 740 pts.
First Author: Hyungwoo Cho
Poster
2016 Gastrointestinal Cancers Symposium
Establishment and validation of prognostic nomograms including HER2 status in metastatic gastric cancer.
First Author: Takeshi Kawakami